Jennerex therapy shrinks tumors in liver cancer patients

Jennerex's genetically modified smallpox vaccine shrunk tumors in liver cancer patients and extended survival by more than a year, a study shows. The company tested Pexa-Vec, the therapy treatment, on 30 individuals with advanced hepatocellular carcinoma. The 16 patients who received a high dose of Pexa-Vec lived a median of 14.1 months after injection, while the 14 who got a low dose lived a median of 6.7 months. More | Abstract

Suggested Articles

Merck has a big target in mind for its pneumococcal vaccine V114: Prevnar 13, the world's best-selling shot—and its phase 3 program shows it.

A Lancet Infectious Diseases study shows antibody response persists for two years or more after a single shot of Merck’s rVSV-ZEBOV vaccine.

Behind the under-pressure blockbuster Prevnar 13 are several pipeline vaccines Pfizer hopes will propel future growth.